Huahai Pharmaceutical's subsidiaries Huaaotai Bio and Huabo Bio HB0028 Injection were approved for clinical use
Watson Bio's bivalent HPV vaccine is about to be approved
Junjing Bio's fourth-generation EGFR inhibitor applied for clinical application
Junshi Bio's anti-CD112R monoclonal antibody was approved for clinical use in the United States
Suzhou Yilian Bio's YL201 clinical trial application obtained the US FDA's implied license
Yifang Bio's new KRAS G12C inhibitor achieved positive results in Phase 1 clinical trials
Wanfu Bio has changed the registration information of the novel coronavirus antigen detection kit
The first general-purpose CAR-T in China was approved for clinical use from Beiheng Bio
Mingde Bio's novel coronavirus antigen detection reagent obtains medical device registration certificate
Innovent Bio won the 7th blockbuster variety and 25 innovative drugs exposed
Junshi Bio's Toripalimab in the Treatment of Small Cell Lung Cancer Receives FDA Orphan Drug Designation
Junshi Bio's Toripalimab for the Treatment of Small Cell Lung Cancer Receives Orphan Drug Designation by the U.S. FDA
Green Bamboo Bio uses Lonza GS Xceed(R) gene expression system to develop recombinant shingles vaccine and bispecific antibody
Innovent Bio announced that its anti-CTLA-4 monoclonal antibody IBI310 has been included
WHO clarifies that one dose of HPV vaccine can cause Zhifei Bio to plummet
Liantuo Bio has introduced over 200 million US dollars!
The preparation method of zeolite bio-organic fertilizer won the award
49 listed companies disclosed their 2022 first quarter reports, including 5 pharmaceutical companies including Keqian Bio and Chengda Pharmaceutical
The country has clearly accelerated the development of bio-based chemical fibers, and Shenghong has advanced its layout
Ketuo Bio wishes the 2022 CIFST Student Innovation Activity Online Kick-off Meeting to be Successfully Held